Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
暂无分享,去创建一个
Yair Lotan | Sudhir Srivastava | Ziding Feng | Daniel W Chan | Rosalia Viterbo | Martin G Sanda | Alan W Partin | Jacob Kagan | Lori Sokoll | Samir S Taneja | Daniel W Lin | John T. Wei | D. Chan | A. Kibel | A. Partin | Y. Lotan | L. Sokoll | Ziding Feng | S. Taneja | M. Sanda | I. Thompson | S. Srivastava | D. Lin | R. Viterbo | J. Kagan | Jackie Dahlgren | John T Wei | Elissa Brown | Ian Thompson | Adam S Kibel | J Erik Busby | Mohamed Bidair | Aron Y Joon | Jackie Dahlgren | Elissa C. Brown | M. Bidair | J. E. Busby | D. Chan
[1] Ziding Feng,et al. Evaluating the Predictiveness of a Continuous Marker , 2007, Biometrics.
[2] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[3] John T. Wei,et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. , 2006, Journal of the National Cancer Institute.
[4] J Alfred Witjes,et al. The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance , 2007, Clinical Cancer Research.
[5] Margaret Sullivan Pepe,et al. Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility , 2009, Statistics in medicine.
[6] Peter H Gann,et al. Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.
[7] Donna P Ankerst,et al. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. , 2009, The Journal of urology.
[8] A. SolerRoselló,et al. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study. , 1988 .
[9] T. Hedner,et al. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.
[10] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[11] Mesut Remzi,et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. , 2008, European urology.
[12] Christina Bougatsos,et al. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.
[13] C. Ramos,et al. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. , 2013, Urologic oncology.
[14] Antoinette M Stroup,et al. Prostate cancer early detection , 2010 .
[15] Seongjoon Koo,et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.
[16] C G Chute,et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.
[17] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[18] J. Raman,et al. Complications following prostate needle biopsy requiring hospital admission or emergency department visits – experience from 1000 consecutive cases , 2012, BJU international.
[19] Jerome P. Richie,et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.
[20] P. Troncoso,et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. , 2008, The Journal of urology.
[21] D Andrew Loblaw,et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[23] A. Haese*,et al. Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion , 2012, World Journal of Urology.
[24] L. Kiemeney,et al. DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .
[25] F. Saad,et al. uPM3, a new molecular urine test for the detection of prostate cancer. , 2004, Urology.
[26] Thomas Anil,et al. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. , 2011, Urology.
[27] E. Metter,et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.
[28] Sudhir Srivastava,et al. A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[29] Mohammad Hassan Murad,et al. Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.
[30] W. Isaacs,et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.
[31] U. Stenman,et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.
[32] John T. Wei,et al. Rational approach to implementation of prostate cancer antigen 3 into clinical care , 2009, Cancer.
[33] J. Groskopf,et al. PCA3: from basic molecular science to the clinical lab. , 2011, Cancer letters.
[34] John T. Wei,et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. , 2011, The Journal of urology.
[35] Leonard S. Marks,et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.
[36] Yingye Zheng,et al. Integrating the predictiveness of a marker with its performance as a classifier. , 2007, American journal of epidemiology.
[37] Amy Blase,et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.
[38] Ziding Feng,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.
[39] Martina Tinzl,et al. DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. , 2004, European urology.